Legend:
CC = Baltimore Convention Center, H = Hilton Baltimore
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
659 * !
|
Thu, 8/3/2017,
10:30 AM -
12:20 PM
|
CC-342
|
|
Clinical Trial Research — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Brian Wiens, Tobira Therapeutics
|
|
10:50 AM
|
A Robust Paradigm of Finding the Maximum Tolerated Dose in Phase I Cancer Clinical Trials
—
Tina Young, Bristol-Myers Squibb ; Dirk Moore, Rutgers School of Public Health ; Yong Lin, Rutgers ; Weichung Joe Shih, Rutgers School of Public Health
|
|
11:05 AM
|
Impact of Assessment of Schedule Interval Change on Median Progression-Free Survival Estimate
—
Shuyan Wan, Merck
|
|
11:20 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy
—
Michelle DeVeaux, Yale University ; Daniel Zelterman, Yale University ; Michael Kane, Yale University
|
|
11:35 AM
|
Program Success Criteria for Drug Approval: P Value vs. Bayesian Posterior Probability
—
Meihua Wang, Merck & Co. ; Frank Liu, Merck & Co. Inc.
|
|
11:50 AM
|
Constructing a Synthetic Control Arm from Previous Clinical Trials, with Application to Cancer Trials
—
Steven Schwager, Medidata Solutions ; Michael Elashoff, Medidata Solutions ; Philip Beineke, Medidata Solutions ; Ruthanna Davi, Medidata Solutions
|
|
12:05 PM
|
Select a Better Treatment Using Efficacy Safety and Patients' Preference
—
Kao-Tai Tsai
|
|
